Exforge HCT

Exforge HCT is a brand name of amlodipine/hydrochlorothiazide/valsartan, approved by the FDA in the following formulation(s):

EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: April 30, 2009
  
  Strength(s): 10MG;12.5MG;160MG, 10MG;25MG;160MG, 10MG;25MG;320MG ^[RLD], 5MG;12.5MG;160MG, 5MG;25MG;160MG
  

Has a generic version of Exforge HCT been approved?

No. There is currently no therapeutically equivalent version of Exforge HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Exforge HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Acyl compounds
  Patent 5,399,578
  Issued: March 21, 1995
  Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
  Assignee(s): Ciba-Geigy Corp
  Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.
  
  Patent expiration dates:
  
  
  • March 21, 2012
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 21, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Solid oral dosage forms of valsartan
  Patent 6,294,197
  Issued: September 25, 2001
  Inventor(s): Wagner; Robert Frank & Katakuse; Yoshimitsu & Taike; Takashi & Yamato; Fujiki & Kohlmeyer; Manfred
  Assignee(s): Novartis AG
  The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
  
  Patent expiration dates:
  
  
  • June 18, 2017
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug product
  
  
  
  • December 18, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition containing anti-hypertensive agents
  Patent 8,101,599
  Issued: January 24, 2012
  Inventor(s): Shetty; Suraj S & Webb; Randy L
  Assignee(s): Novartis AG
  The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.
  
  Patent expiration dates:
  
  
  • May 16, 2023
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 30, 2012 - NEW COMBINATION
  
  

See also...

• Exforge HCT Consumer Information (Drugs.com)
• Exforge HCT Consumer Information (Wolters Kluwer)
• Exforge HCT Consumer Information (Cerner Multum)
• Exforge HCT Advanced Consumer Information (Micromedex)
• Amlodipine/Valsartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Amlodipine, hydrochlorothiazide, and valsartan Consumer Information (Cerner Multum)
• Amlodipine, valsartan, and hydrochlorothiazide Advanced Consumer Information (Micromedex)